EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 3.0

Treatment of Nongout Joint Deposition Diseases: An Update

Tristan Pascart iD, Pascal Richette, René-Marc Flipo

Arthritis · 08.05.2014 · 2014 · 1-8

DOI: 10.1155/2014/375202 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Arthritis, erschienen am 08.05.2014. Verfasst von Tristan Pascart und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Saint-Philibert Hospital, Service de Rhumatologie, Lille Catholic University, rue du Grand But, 59160 Lomme, France ; Dep…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This update develops the actual therapeutic options in the management of the joint involvement of calcium pyrophosphate deposition disease (CPPD), basic calcium phosphate (BCP) deposition disease, hemochromatosis (HH), ochronosis, oxalosis, and Wilson’s disease. Conventional pharmaceutical treatment provides benefits for most diseases. Anti-interleukine-1 (IL-1) treatment could provide similar results in CPPD than in gout flares. There is only limited evidence about the efficacy of preventive long-term colchicine intake, methotrexate, and hydroxychloroquine in chronic CPPD. Needle aspiration and lavage have satisfactory short and midterm results in BCP. Extracorporeal shockwave therapy has also proved its efficacy for high-doses regimes. Phlebotomy does not seem to have shown real efficacy on joint involvement in HH so far. Iron chelators’ effects have not been assessed on joint involvement either, while IL-1 blockade may prove useful. NSAIDs have limited efficacy on joint involvement of oxalosis, while colchicine and steroids have not been assessed either. The use of nitisinone for ochronotic arthropathy is still much debated, but it could provide beneficial effects on joint involvement. The effects of copper chelators have not been assessed either in the joint involvement of Wilson’s disease. NSAIDs should be avoided because of the liver affection they may worsen.

Autor:innen und Institutionen

  • Department of Rheumatology, Saint-Philibert Hospital, Service de Rhumatologie, Lille Catholic University, rue du Grand But, 59160 Lomme, France ; Department of Rheumatology, Roger Salengro Hospital, Lille 2 University,…
  • Federation of Rheumatology, Lariboisiere Hospital, Assistance Publique-Hopitaux de Paris, UFR Medicale, Paris 7 University, 75475 Paris Cedex 10, France.
  • Department of Rheumatology, Roger Salengro Hospital, Lille 2 University, rue Emile Laine, 59037 Lille Cedex, France.

ORCID-Profile: Tristan Pascart

Zitieren

APA

Pascart, T., Richette, P., & Flipo, R. M. (2014). Treatment of Nongout Joint Deposition Diseases: An Update. Arthritis, 2014, 1-8. https://doi.org/10.1155/2014/375202

Vancouver

Pascart T, Richette P, Flipo RM. Treatment of Nongout Joint Deposition Diseases: An Update. Arthritis. 2014;2014:1-8. doi:10.1155/2014/375202

BibTeX
@article{Pascart2014,
  author = {Pascart, Tristan and Richette, Pascal and Flipo, René-Marc},
  title = {Treatment of Nongout Joint Deposition Diseases: An Update},
  journal = {Arthritis},
  year = {2014},
  volume = {2014},
  pages = {1--8},
  doi = {10.1155/2014/375202}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche